Limits of lecanemab, a new drug approved to treat Alzheimer's
Breakthrough, or not? On The Long View, we focused on the long road to finding the best way to treat Alzheimer's disease. Our Contributing editor Neal Milner joined us in-studio
Good overall look: "FDA approves Alzheimer’s drug lecanemab amid safety concerns"
A critic scientist’s experience: Essay by Rachael Neve
Silberner’s article: “The Reason There’s Been No Cure for Alzheimer’s”
This interview aired on The Conversation on Jan. 11, 2023. The Conversation airs weekdays at 11 a.m. on HPR-1.